The Evolving Role of Immunotherapy in the Treatment of Genitourinary Cancers: An Update for Pharmacists

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant Merck & Company, Inc.

Registration & Dates for Activities

Tuesday, August 10, 2021
2:00-3:15 PM ET

FACULTY

Kirollos S. Hanna, PharmD, BCPS, BCOP
Oncology Pharmacy Manager
M Health Fairview - Maple Grove
Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Rochester, Minnesota

ACCREDITATION STATEMENTS

PHARMACY
acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-21-059-L01-P
Credits: 1.25 hours (0.125 ceu)

Type of Activity: Application
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 75 minutes

TARGET AUDIENCE

This accredited activity has been designed for oncology, managed care and specialty pharmacists.

HOW TO EARN CREDIT

Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live webinar; and 3) complete the evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.

Goal

To provide oncology, managed care, and specialty pharmacists with advanced knowledge about optimal and emerging immune-oncology treatment options for adult patients with genitourinary cancers, such that they can optimize patient care.

LEARNING OBJECTIVES

At the conclusion of this program, the learner will be able to do the following:

  • Discuss current and emerging immune checkpoint inhibitor (ICI) use in genitourinary cancer treatment alone and in combination regimens
  • Identify challenges to and best practices for ICI use in genitourinary cancer treatment
  • Demonstrate approaches to effectively recognize and manage immune-related adverse events of immunotherapies alone and in combination regimens for genitourinary cancer treatment

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, or Merck & Company, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.